BRIEF published on 08/02/2024 at 22:35, 1 year 7 months ago DBV Technologies : Informations au 31 juillet 2024 sur le nombre d'actions et de droits de vote Droits De Vote Capital Social AMF DBV Technologies NYSE Euronext Paris
BRIEF published on 08/02/2024 at 22:35, 1 year 7 months ago DBV Technologies: Information as of July 31, 2024 on the number of shares and voting rights Share Capital Voting Rights AMF DBV Technologies NYSE Euronext Paris
PRESS RELEASE published on 08/02/2024 at 22:30, 1 year 7 months ago Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2024 Nombre total des droits de vote et d’actions au 31 juillet 2024 pour NYSE Euronext Paris (Code ISIN: FR 0010417345) : 96 498 927 actions, 96 214 457 droits de vote Autorité Des Marchés Financiers Droits De Vote Capital Social Actions NYSE Euronext Paris
PRESS RELEASE published on 08/02/2024 at 22:30, 1 year 7 months ago Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 Details of total voting rights and shares of the Company as of July 31, 2024 under AMF regulations Voting Rights Shares AMF Regulations Company July 31 2024
BRIEF published on 07/30/2024 at 23:35, 1 year 7 months ago DBV Technologies met à disposition son Rapport Financier Semestriel 2024 AMF Rapport Financier DBV Technologies Allergies Alimentaires Viaskin™
BRIEF published on 07/30/2024 at 23:35, 1 year 7 months ago DBV Technologies makes its 2024 Half-Year Financial Report available AMF Financial Report DBV Technologies Food Allergy Viaskin™
PRESS RELEASE published on 07/30/2024 at 23:30, 1 year 7 months ago DBV Technologies publie son Rapport Financier Semestriel 2024 ? Modalités de mise à disposition ou de consultation DBV Technologies publie son Rapport Financier Semestriel 2024 et annonce sa disponibilité pour consultation en ligne ou par demande Biopharmaceutique Rapport Financier DBV Technologies Allergies Alimentaires Viaskin
PRESS RELEASE published on 07/30/2024 at 23:30, 1 year 7 months ago DBV Technologies Announces Filing of 2024 Half-Year Report ? Conditions for Accessing or Consulting the Report DBV Technologies files 2024 Half-Year Report with AMF and offers access via website or request. Company develops treatments for food allergies using Viaskin platform AMF DBV Technologies Food Allergies 2024 Half-Year Report Viaskin Platform
BRIEF published on 07/30/2024 at 22:35, 1 year 7 months ago DBV Technologies : Avancées pour Viaskin Peanut et résultats financiers au premier semestre 2024 Résultats Financiers Recherche Et Développement DBV Technologies Allergies Alimentaires Viaskin Peanut
Published on 03/23/2026 at 14:05, 40 minutes ago Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Published on 03/23/2026 at 14:00, 45 minutes ago BlackBerry AtHoc Advances Command Center for Faster Response and Tighter Control During Critical Operations
Published on 03/23/2026 at 13:05, 1 hour 40 minutes ago SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Published on 03/23/2026 at 12:32, 2 hours 13 minutes ago Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 2 hours 15 minutes ago Digi Power X to Announce 2025 Year End Financial Results on March 31st
Published on 03/23/2026 at 14:30, 15 minutes ago Solvias Earns EcoVadis Bronze Medal, Ranking in Top 35% of Companies for Sustainability Performance
Published on 03/23/2026 at 14:30, 15 minutes ago Belvilla Expands in Germany with Hambachtal Holiday Park in Oberhambach
Published on 03/23/2026 at 14:24, 21 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 03/23/2026 at 08:10, 6 hours 35 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 19 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 19 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 20 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 20 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
